The neurobiology of stereotypic behaviors and stereotypic movement disorders

Psychiatric Annals

Volumn 28, Issue 6, 1998, Pages 317-323

  Grossman, Robert ^a   Verobyev, Leonid ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0032392616     PISSN: 00485713     EISSN: None     Source Type: Journal    
DOI: 10.3928/0048-5713-19980601-09     Document Type: Article

References (113)

1. Breese GR, Baumeister AA, McGown T, et al. Behavioral differences between neonatal and adult 6-hydroxydopamine-treated rats to dopamine agonists: relevance to neurological symptoms in clinical syndromes with reduced brain dopamine. J Pharmacol Exp Ther. 1984;231:343-354.
2. Goodman WK, McDougle CJ, Price LH, et al. Beyond the serotonin hypothesis: a role for dopamine in some forms of obsessive compulsive disorder? J Clin Psychiatry. 1990;S51:36-43.
3. Lewis MH, Gluck JP, Beachamp AJ, Keresztury MF, Mailman RB. Long term effects of early social isolation in Macaca mulatta: In vivo evidence for changes in dopamine receptor function. Brain Res. 1990;513:67-73.
4. Martin L, Spicer DW, Lewis MH, Gluck JP, Cork LC. Social deprivation in infant rhesus monkeys alters the chemoarchitecture of the brain: I. Subcortical regions. J Neurosci. 1991;11:3344-3358.
5. Ferre S, Von Euler G, Johanson B, Fredholm B, Fuxe K. Stimulation of high affinityadenosine A-2 receptors decreases the affinity of dopamine D-2 receptors in rat striatal membranes. Proc Natl Acad Sci U S A. 1991;88:7238-7241.
6. Cooper JR, Bloom FE, Roth RH. The Biochemical Basis of Neuropharmacology. Seventh Edition. Oxford University Press, Inc. New York; 1996.
7. Johanson CE. Assessment of the dependence potential of cocaine in animals. National Institute on Drug Abuse Research Monograph Series 1984;50:54-71.
8. Willemse T. The effect of dopamine antagonists on psychogenic alopecia in cats. Proceedings of the Second World Congress of Veterinary Dermatology: May 13-16; Montreal, Quebec, Canada, 1992.
9. Von Borell E, Hurnik JF. The effect of haloperidol on the performance of sterotyped behaviour in sows. Life Sci. 1991;49:309-314.
10. Mikkelsen EJ. Low-dose haloperidol for stereotypic self-injurious behavior in the mentally retarded. New Eng J Med. 1986;315:398-399.
11. Gualtieri CT, Schroeder SR. Pharmacology of self-injurious behavior: preliminary test of the D1 hypothesis. Psychopharmacol Bull. 1989;25:366-371.
12. Lloyd KG, Hornykiewics O, Davidson L, et al. Biochemical evidence of dysfunction of brain neurotransmitters in th Lesch-Nyhan syndrome. New Engl J Med. 1981;305:1106-1111.
13. Dunnett SB, Sirinathsinghji JD, Heavens R, et al. Monoamine deficiency in a transgenic (Hprt-) mouse model of Lesch-Nyhan syndrome. Brain Res. 1989;501:401-406.
14. Jinnah HA, Wojcik BE, Hunt M, et al. Dopamine deficiency in a genetic mouse model of Lesch-Nyhan disease. J Neurosci. 1994;14:1164-1175.
15. Ernst M, Zametkin AJ, Matochik JA, et al. Presynaptic dopaminergic deficits in Lesch-Nyhan disease. N Engl J Med. 1996;334:1568-1572.
16. Lake CR, Ziegler MG. Lesch-Nyhan syndrome: Low dopamine-betahydroxylase activity and diminished sympathetic response to stress and posture. Science. 1977;196:906-906.
17. Silverstein FS, Johnston MV, Hutchinson RJ, et al. Lesch-Nyhan syndrome: CSF neurotransmitter abnormalities. Neurology. 1985;35:907-911.
18. Wong DF, Harris JC, Naidu S, et al. Dopamine transporters are markedly reduced in Lesch-Nyhan disease in vivo. Proc Natl Acad Sci U S A. 1996;93:5539-5543.
19. Goldstein M, Kuga S, Kusano N, et al. Dopamine agonist induced self-mutilative biting behavior in monkeys with unilateral ventromedial tegmental lesions of the brain-stem; Possible pharmacological model for Lesch-Nyhan syndrome. Brain Res Bull. 1986;367:114-119.
20. Watts RW, Spellacy E, Gibbs DA, et al. Clinical, postmortem, biochemical and therapeutic observations on the Lesch-Nyhan syndrome with particular reference to the neurological manifestations. QJM. 1982;51:43-78.
21. Anderson LT, Ernst M, Davis S. Self-injury in Lesch-Nyhan diseases. J Autism Dev Disord. 1994;24:67-81.
22. Robertson MM. The Gilles de la Tourette Syndrome: The current status. Br J Psychiatry, 1989;154:147-169.
23. Robertson MM, Trimble MR, Lees A. Self-injurious behavior and the Gilles de la Tourette syndrome: A clinical study and review of the literature. Psychol Med. 1989;19:611-625.
24. Caine ED. Gilles de la Tourette's syndrome: a review of clinical and research studies and consideration of future directions for investigation. Arch Neurol. 1985;42:393-397.
25. Leckman JF, Goodman WK, Anderson GM, et al. Cerebrospinal fluid biogenic amines in obsessive-compulsive disorder, Tourette's syndrome, and healthy controls. Neuropsychopharmacology, 1995;12:73-86.
26. Singer HS, Hahn IH, Moran TH. Abnormal dopamine uptake sites in postmortem striatum from patients with Tourette's syndrome. Ann Neurol. 1991;30:558-562.
27. Malison RT, McDougle CJ, van Dyck CH, et al. [123I]B-CIT SPECT imaging of striatal dopamine transporter binding in Tourette's disorder. Am J Psychiatry. 1995;152:1359-1361.
28. Wolf SS, Jones DW, Knable MB, et al. Tourette syndrome: Prediction of phenotypic variation in monozygotic twins by caudate nucleus D2 receptor binding. Science. 1996;273:1227.
29. Shapiro AK, Shapiro E. Tourette syndrome: clinical aspects, treatment, and etiology. Semin Neurol. 1982;2:373-385.
30. Bruun KD, Budman CL. Risperidone as a treatment for Tourette's syndrome. J Clin Psychiatry. 1996;57:29-31.
31. Rubin M. Use of atypical antipsychotics in children with mental retardation, autism, and other developmental disabilities. Psychiatric Annals. 1997;27:219-221.
32. Kapur S, Remington G. Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry. 1996;153:466-476.
33. Van Praag HM, Plutchik K, Conte H. The serotonin hypothesis of (auto)aggression. Ann N Y Acad Sci. 1986;487:150-167.
34. Stein DJ, Hollander E, Liebowitz MR. Neurobiology of impulsivity and impulse control disorders. J Neuropsychiatry Clin Neurosci. 1993;5:9-17.
35. New AS, Trestman RL, Mitropoulou V, Benishay DS. Serotonergic function and self-injurious behavior in personality disorder patients. Psychiatry Rss. 1997;69:17-26.
36. Stein DJ, Dodman NH, Borechelt P, Hollander E. Behavior disorders in veterinary practice: relevance to psychiatry. Compr Psychiatry. 1994;35:275-285.
37. Grindlinger HM, Ramsay E. Compulsive feather picking in birds. Arch Gen Psychiatry. 1991;48:857.
38. Rapoport J, Ryland D, Kriete M. Drug treatment of canine acral lick: an animal model of obsessive-compulsive disorder. Arch Gen Psychiatry. 1992;49:517-521.
39. Yamaguchi K, Nabeshima T, Kameyama T. Potentiation of the phencyclidine induced dopamine behaviours in rats after pretreatment with serotonin depletors. Journal of Pharmacobiodynamics.
40. Zohar J, Insel TR. Obsessive-compulsive disorder: psychobiological approaches to diagnosis, treatment, and pathophysiology. Biol Psychiatry. 1987;22:667-687.
41. Stein DJ. The neurobiology of obsessive-compulsive disorder. The Neuroscientist. 1996;2:300-305.
42. Primeau F; Fontaine R. Obsessive disorder with self-mutilation: A subgroup responsive to pharmacotherapy. Can J Psychiatry. 1987;32:699-701.
43. Swedo SE, Leonard HL, Rapoport JL, Lenane MC. A double-blind comparison of clomipramine and desipramine in the treatment of trichotillomania (hair pulling). N Engl J Med. 1989;321:497-501.
44. Bodfish JM, Crawford TM, Powell SB, et al. Compulsions in adults with mental retardation: prevalence, phenomenology, and comorbidity with stereotypy and self-injury. Am J Ment Retard. 1995;100:183-192.
45. Mikkelsen EJ, Albert LG, Emens M, et al. The efficacy of aritidepressant medication for individuals with mental retardation. Psychiatric Annals. 1997;27:198-206.
46. Winchel RM, Stanley M. Self-injurious behavior: A review of the behavior and biology of self-mutilation. Am J Psychiatry. 1991;148:306-317.
47. Anderson GM, Pollack ES, Chatterjee D, Leckman JF, Riddle MA, Cohen DJ: Brain monoamines and amino acids in Gilles de la Tourette's syndrome: a preliminary studv of subcortical regions. Arch Gen Psychiatry. 1992;49:584-586.
48. Rasmusson AM, Anderson GM, Lynch KA, et al. A preliminary study of tryptophan depletion on tics, obsessive-compulsive symptoms, and mood in Tourette's syndrome. Biol Psychiatry. 1997;41:117-121.
49. Caine ED, Polinsky RJ, Ebert MH, et al. Trial of chlorimipramine and desipramine for Gilles de la Tourette syndrome. Ann Neurol. 1979;5:305-306.
50. Kurlan R, Como PG, Deeley C, et al. A pilot controlled study of fluoxetine for obsessive-compulsive symptoms in children with Tourette's syndrome. Clin Neuropharmacol. 1993;16:167-172.
51. Eapen V, Trimble MR, Robertson MM. The use of fluoxetine in Gilles de la Tourotte syndrome and obsessive compulsive behaviors: preliminary clinical experience. Prog Neuropsychopharm Biol Psychiatry. 1996;20:737-743.
52. Hawkridge S, Stein DJ, Bouwer C. Combining neuroleptics with serotonin specific reuptake inhibitors in Tourette's syndrome. J Am Acad Child Adolesc Psychiatry. 1996;35:703-704.
53. Daniel WL, Higgins JV. Biochemical and genetic investigations of the de Lange syndrome. Am J Dis Child. 1971;121:401.
54. Singh NN, Pulman RM. Self-injury in the de Lange syndrome. J Ment Defic Res. 1979;23:79-84.
55. Greenberg A, Coleman M. Depressed whole blood serotonin levels associated with behavioral abnormalities in the de Lange syndrome. Pediatrics. 1973;52:720-724.
56. Prader A, Labhart A, Willi H. Ein syndrom von adipositas, kleinwuchs, kryptochismus und oligophrenie nach myatonieartigem zustand im neugeborenenalter. Schweizerische Medizinische Wochenschrift. 1956;86:1260-1261.
57. Holm VA. The diagnosis of Prader-Willi syndrome, in Prader-Willi Syndrome, edited by Holm VA, Sulzbacher SJ, Pipes P. Baltimore; University Park Press; 1981:27-44.
58. Clarke DJ, Waters J, Corbett JA. Adults with Prader-Willi syndrome: Abnormalities of sleep and behavior. Journal of the Royal Society of Medicine. 1989;82:21-24.
59. Stein DJ, Keating J, Zar HJ, et al: A survey of the phenomenology and pharmacotherapy of compulsive and impulsive-aggressive symptoms in Prader-Willi syndrome. J Neuropsychiatry Clin Neurosci. 1994;6:23-29.
60. Curzon G. Serotonin and appetite, in The Neuropharmacology of Serotonin. Edited by Whitaker-Azmita PM, Peroutka SJ. New York, New York Academy of Sciences, 1990.
61. Jimersen DC, Lesem MD, Hegg AP, Brewerton TD. Serotonin in human eating disorders, in The Nouropharmacology of Serotonin. Edited by Whitaker-Azmita PM, Peroutka SJ. New York, New York Academy of Sciences; 1990.
62. Schepis C, Failla P, Siragusa M, et al. Skin-picking: the best cutaneous feature in the recognition of Prader-Willi syndrome. Int J Dermatol. 1994;33:866-867.
63. Stein DJ, Hutt C, Spitz J, et al. Compulsive picking and obsessive-compulsive behaviour. Psychosomatics. 1993;34:177-181.
64. Selikowitz M, sunman J, Pendergast A, Wright S. Fenfluramine in Prader-Willi syndrome: A double-blind, placebo controlled trial. Arch Dis Childhood. 1990;65:112-114.]
65. Warnock JK, Kestenbaum T. Pharmacologic treatment of severe skin-picking behaviors in Prader-Willi syndrome. Two case reports. Arch Dermatol. 1992;128:1623-1625.
66. Cook EH. Autism: review of neurochemical investigation. Synapse. 1990;6:292-308.
67. Hoshino Y, Tachibana R, Watanabe M, et al. Serotonin metabolism and hypothalamic-pituitary function in children with infantile autism and minimal brain dysfunction. Jpn J Psychiatry Neurol. 1984;25:937-945.
68. McBride PA, Anderson GM, Hertig ME, et al. Serotonergic responsivity in male young adults with autistic disorder: results of a pilot study. Arch Gen Psychiatry. 1989;46:213-221.
69. McDougle CJ, Naylor ST, Cohen DJ, et al. Effects of tryptophan depletion in drug-free adults with autistic disorder. Arch Gen Psychiatry. 1996a;53:993-1000.
70. Cook EH Jr, Courchesne R, Lord C, et al. Evidence of linkage between the serotonin transporter and autistic disorder. Mol Psychiatry. 1997;2:247-250.
71. McDougle CJ, Price LH, Volkmar FR, et al. Clomipramine in autism: preliminary evidence of efficacy. J Am Acad Child Adolesc Psychiatry. 1992;31:739-746.
72. Cook EH, Rowlett R, Jaselskis C, et al. Fluoxetine treatment of children and adults with autistic disorder and mental retardation. J Am. Acad Child Adolesc Psychiatry. 1992;31:739-745.
73. Hollings JA, Kelley LA, Gabrielli WP, et al. Sertraline response in adults with mental retardation and autistic disorder. J Clin Psychiatry. 1996;57:333-336.
74. McDougle CJ, Naylor ST, Cohen DJ, et al. A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder. Arch. Gen Psychiatry. 1996b;53:1001-1008.
75. Gordon CT, State RC, Nelson JE, et al. A double-blind comparison of clomipramine, desipramine, and placebo in the treatment of autistic disorder. Arch Gen Psychiatry. 1993;50:441-447.
76. Stern LM, Walker MK, Sawyer MG, et al. A controlled crossover trial of fenfluramine in autism. J Chid Psychol Psychiatry. 1990;31:569-585.
77. Campbell M, Adams P, Small AM, et al. Efficacy and safety of fenfluramine in autistic children. J Am Acad Child Adolesc Psychiatry. 1988;27:434-439.
78. Leventhal BL, Cook EH, Morfold M, et al. Clinical and neurochemical effects of fenfluramine in children with autism. J Neuropsychiatry Clin Neurosci. 1993;5:307-315.
79. Sandman CA. The opiate hypothesis in autism and self-injury. J Child Adolesc Psychopharm. 1990;1:237-248.
80. Herman BH. A possible role of proopiomelanocortin peptides in self-injurious behavior. Prog Neuropsychopharmacol Biol Psychiatry. 1990;14S:109-139.
81. Cronin GM, Wiepkema PR, van Ree JM. Endogenous opioids are involved in abnormal stereotyped behaviours of tethered sows. Neuropeptides. 1985;6:527-530.
82. Cronin GM, Wiepkema PR, Van Ree JM. Endorphins implicated in stereotypies of tethered sows. Experientia. 1986;42:198-199.
83. Meyer ME, McLaurin BI, Meyer ME. Intra-accumbens o-sub-1-opioid agonist, pCl-DPDPE, differentially affects patterns of locomotor activity. Pharmacol, Biochem Behav. 1995;51:359-362.
84. Brown SA, Crowell-Davis S, Malcolm T, Edwards P. Naloxone-responsive compulsive tail chasing in a dog. J Am Vet Med Assoc. 1987;190:884-886.
85. Herman BH, Hammock MK, Egan J, et al. A role of opioid peptides in self-injurious behavior: dissociation from autonomic nervous system functioning. Dev Pharmacol Ther. 1989;12:81-89.
86. Cataldo MF, Harris J. The biological basis for self-injury in the mentally retarded. Analysis and Intervention in Developmental Disabilities. 1982;2:21-39.
87. Sandman CA. B-Endorphin dysregulation in autistic and self-injurious behavior: a neurodevelopmental hypothesis. Synapse. 1988;2:193-199.
88. Pies RW, Popli AP. Self-injurious behavior: pathophysiology and implications for treatment. J Clin Psychiatry. 1995;56:580-588.
89. Osman OT, Loschen EL. Self-injurious behavior in the developmentally disabled: pharmacologic treatment. Psychopharmacol Bull. 1992;28:439-449.
90. Willemsen-Swinkels SH, Buitelaar JK, Nijhof GJ, et al. Failure of naltrexone hydrochloride to reduce self-injurious and autistic behavior in mentally retarded adults. Double-blind placebo-controlled studies. Arch Gen Psychiatry. 1995;52:766-773.
91. Panskepp J. A neurochemical theory of autism. Trends Neurosci. 1979;2:174-177.
92. Chamberlain ES, Herman BH. A novel biochemical model linking dysfunctions in brain melatonin, proopiomelanocortin peptides, and serotonin in autism. Biol Psychiatry. 1990;28:773-793.
93. Haber SN, Kowall NW, Von Sattell, et al. Gilles de la Tourette's syndrome: A postmortem neuropathological and immunohistochemical study. J Neurol Sci. 1986; 76:225-241.
94. Leckman JF, Riddle MA, Berrettini WH, et al. Elevated CSF dynorphin A[1-8] in Tourette's syndrome. Life Sci. 1988;43:2015-2023.
95. McConville BJ, Norman AB, Fogelson MH, et al: Sequential use of opioid antagonists and agonists in Tourette's syndrome. Lancet. 1994;343:601.
96. Christenson et al.
97. Breese GR, Hulebak KL, Napier TG, et al. Enhanced muscimol-induced behavioral responses after 6-OHDA lesions. Psychopharmacology. 1967;91:356-362.
98. Kopin IJ. Neurotransmitters and the Lesch-Nyhan syndrome. N Engl J Med. 1981;305:1148-1149.
99. Kastner T, Finesmith R, Walsh K. Long-term administration of valproic acid in the treatment of affective symptoms in people with mental retardation. J Clin Psychopharmacol. 1993;13:448-451.
100. Sarkar M, Kornetsky C. Methamphetamine's action on brain-stimulation reward threshold and stereotypy. Experimental and Clinical, Psychopharmacology. 1995;3:112-117.
101. Winslow J, Insel T. Neuroethological models of OCD. In: The Psychobiology of Obsessive-Compulsive Disorder (eds Zohar J, Hollander E, Insel T.) Springer, New York; 1991:208-226.
102. Bhattacharya SK, Jaiswal AK, Mukhopadhyay M, Datla KP. Clonidine-induced automutilation in mice as a laboratory model for clinical self-injurious behavior. J Psychiatr Res. 1988;22:43-50.
103. Razzak A, Fujiwara M, Ueki S. Automutilation induced by clonidine in mice. Eur J Pharmacol. 1975;30:356-359.
104. Leckman J, Hardin M, Riddle M, et al. Clonidine treatment of Gilles de la Tourette's syndrome. Arch Gen Psychiatry. 1991;48:324-328.
105. Goetz CG, Tanner CM, Wilson HS, et al. Clonidine and Gilles de la Tourette's Syndrome: double blind study using objective rating methods. Ann Neurol. 1987;21:307-310.
106. Ridley, 1984
107. Coscia EM, Fentress JC. Neurological dysfunction expressed in the grooming behavior of developing weaver mutant mice. Behav Genet. 1993;23:533-541.
108. Insel TR. Toward a neuroanatomy of obsessive-compulsive disorder. Arch Gen Psychiatry. 1992;49:739-744.
109. O'Sullivan RL, Rauch SL, Breiter HC, Grachev ID. Reduced basal ganglia volumes in trichotillomania measured via morphometric magnetic resonance imaging. Biol Psychiatry. 1997;42:39-45.
110. Peterson B, Riddle MA, Cohen DJ, et al. Reduced basal ganglia volumes in Tourette's syndrome using three-dimensional reconstruction techniques from magnetic resonance images. Neurology. 1993;43:941-949.
111. Hyde TM, Stacey ME, Coppola R, et al. Cerebral morphometric abnormalities in Tourette's Syndrome: A quantitative MRI study of monozygotic twins. Neurology. 1995:1176-1182.
112. Braun AR, Stoetter B, Randolph C, et al. The functional neuroanatomy of Tourette's syndrome: an FDG-PET study. I. Regional changes in cerebral glucose metabolism differentiating patients and controls. Neuropsychopharmacology. 1993;9:277-291.
113. Braun AR, Randolph C, Stoetter B, et al. The functional neuroanatomy of Tourette's syndrome: an PDG-PET study. II. Relationships between regional cerebral metabolism and associated behavioral and cognitive features of the illness. Neuropsychopharmacology. 1995;13:151-168.